Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Australian experience with total pancreatectomy with islet autotransplantation to treat chronic pancreatitis
Author: Bampton, T.J.
Holmes-Walker, D.J.
Drogemuller, C.J.
Radford, T.
Anderson, P.
Etherton, C.
Russell, C.H.
Khurana, S.
Torpy, D.J.
Couper, J.J.
Couper, R.L.T.
Macintyre, P.
Neo, E.L.
Benitez-Aguirre, P.
Thomas, G.
Loudovaris, T.
Thomas, H.E.
Palmer, L.J.
Wu, D.
Rogers, N.M.
et al.
Citation: ANZ Journal of Surgery, 2021; 91(12):2663-2668
Publisher: Wiley
Issue Date: 2021
ISSN: 1445-1433
Statement of
Tristan J. Bampton, D. Jane Holmes-Walker, Chris J. Drogemuller, Toni Radford, Patricia Anderson, C. Etherton, C. H. Russell, S. Khurana, David J. Torpy, J. J. Couper, R. L. T. Couper, Pamela Macintyre, E. L. Neo, Paul Benitez-Aguirre, G. Thomas, T. Loudovaris, H. E. Thomas, Lyle J. Palmer, Denghao Wu, Natasha M. Rogers, L. Williams, W. J. Hawthorne, P. J. O, Connell, Tom W. Kay, Henry Pleass, John W. Chen, and P. Toby Coates, Australian Islet Consortium
Abstract: BACKGROUND: This study aimed to describe the clinical outcomes of total pancreatectomy with islet autotransplantation (TP-IAT) in Australia. METHODS: Individuals selected for TP-IAT surgery according to the Minnesota Criteria (Appendix) without evidence of diabetes were evaluated including time to transplantation from pancreatectomy, islet numbers infused and post-transplantation HbA1c, C-peptide, total daily insulin and analgesic requirement. RESULTS: Sixteen individuals underwent TP-IAT from Australia and New Zealand between 2010 and 2020. Two recipients are deceased. The median islet equivalents/kg infused was 4244 (interquartile range (IQR) 2290-7300). The median C-peptide 1 month post-TP-IAT was 384 (IQR 210-579) pmol/L and at median 29.5 (IQR 14.5-46.5) months from transplant was 395 (IQR 139-862) pmol/L. Insulin independence was achieved in eight of 15 (53.3%) surviving recipients. A higher islet equivalents transplanted was most strongly associated with the likelihood of insulin independence (P < 0.05). Of the 15 surviving recipients, 14 demonstrated substantial reduction in analgesic requirement. CONCLUSION: The TP-IAT programme in Australia has been a successful new therapy for the management of individuals with chronic pancreatitis including hereditary forms refractory to medical treatment to improve pain management with 50% insulin independence rates.
Keywords: auto-islet transplantation
chronic pancreatitis
hereditary pancreatitis
Description: First published: 06 May 2021
Rights: © 2021 Royal Australasian College of Surgeons.
DOI: 10.1111/ans.16853
Published version:
Appears in Collections:Aurora harvest 4
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.